=== МЕТАДАННЫЕ ===
{
  "original_filename": "More Than a Cleanup Crew_ The Expanding Biology of Efferocytosis _ Arteriosclerosis, Thrombosis, and Vascular Biology.html",
  "converted_date": "2026-01-31T14:51:23.438878",
  "file_size_bytes": 657960,
  "original_format": "html",
  "document_type": "Articles",
  "source_folder": "Articles",
  "full_path": "00_RAW_CARDIOLOGY/Articles/More Than a Cleanup Crew_ The Expanding Biology of Efferocytosis _ Arteriosclerosis, Thrombosis, and Vascular Biology.html"
}

=== СОДЕРЖАНИЕ ===
More Than a Cleanup Crew: The Expanding Biology of Efferocytosis | Arteriosclerosis, Thrombosis, and Vascular Biology
Skip to main content
Advertisement
Become a memberVolunteerDonate
JournalsBrowseCollectionsSubjectsAHA Journal PodcastsTrend WatchResourcesCMEAHA Journals @ MeetingsJournal MetricsEarly Career ResourcesInformationFor AuthorsFor ReviewersFor SubscribersFor International UsersAlerts
Shopping cart with
0
item
Cart
Search
Sign in
REGISTER
Quick Search in JournalsEnter search termQuick Search anywhereEnter search termQuick search in CitationsJournalYearVolumeIssuePageSearching:This JournalThis JournalAnywhereCitation
Advanced Search
Search
navigate the sidebar menu
Sign in
REGISTER
Quick Search anywhereEnter search term
Publications
Arteriosclerosis, Thrombosis, and Vascular Biology
Current Issue
Archive
Journal Information
About ATVB
Author
Instructions
Editorial
Board
Meet the Editors
Information for
Advertisers
Features
ATVB_net Blog
ATVB In Focus
Lecture Series
Reviews
Early Career
Resources
ATVB Journal
Awards
Circulation
Circulation Research
Hypertension
Stroke
Journal of the American Heart Association
Circulation: Arrhythmia and Electrophysiology
Circulation: Cardiovascular Imaging
Circulation: Cardiovascular Interventions
Circulation: Population Health and Outcomes
Circulation: Genomic and Precision Medicine
Circulation: Heart Failure
Stroke: Vascular and Interventional Neurology
Annals of Internal Medicine: Clinical Cases
Information
For Authors
For Reviewers
For Subscribers
For International Users
Submit & Publish
Submit to the AHA
Editorial Policies
Open Science
Value of Many Voices
Publishing with the AHA
Open Access Information
Resources
AHA Journals CME
AHA Journals @ Meetings
Metrics
AHA Journals Podcast Network
Early Career Resources
Trend Watch
Professional Heart Daily
AHA Newsroom
Current Issue
Archive
Journal Information
About ATVB
Author
Instructions
Editorial
Board
Meet the Editors
Information for
Advertisers
Features
ATVB_net Blog
ATVB In Focus
Lecture Series
Reviews
Early Career
Resources
ATVB Journal
Awards
Submit
Reference #1
Review ArticleOriginally Published 18 December 2025More Than a Cleanup Crew: The Expanding Biology of EfferocytosisRajan Pandit, Hannah Hillman https://orcid.org/0009-0002-5448-3143, Jesse W. Williams https://orcid.org/0000-0003-3815-0891, and Arif Yurdagul Jr https://orcid.org/0000-0002-7613-6313 arif.yurdagul@lsuhs.eduAuthor Info & AffiliationsArteriosclerosis, Thrombosis, and Vascular BiologyVolume 46, Number 2https://doi.org/10.1161/ATVBAHA.125.323211
230MetricsTotal Downloads230Last 12 Months230View all metrics
Track CitationsAdd to favorites
Get AccessContentsAbstractGraphical AbstractReferenceseLettersInformation & AuthorsMetrics & CitationsGet AccessReferencesFiguresTablesMediaShareAbstractEfferocytosis, the process by which phagocytes clear apoptotic cells, is essential for tissue homeostasis, inflammation resolution, and repair. Once considered a passive waste-disposal process, efferocytosis is now recognized as a dynamic, immunometabolic program that integrates apoptotic cell clearance with metabolic reprogramming and inflammation resolution. In cardiovascular contexts, efficient efferocytosis limits necrosis, enhances the deposition of wound healing matrix proteins, and promotes tissue healing, whereas impaired clearance drives chronic inflammation and maladaptive tissue remodeling. We review the molecular mechanisms governing efferocytosis, including the interplay of find-me, eat-me, and don’t-eat-me signals with receptor-mediated cytoskeletal remodeling and lysosomal degradation. We highlight how efferocytosis drives lipid efflux, fatty acid oxidation, amino acid catabolism, and nucleotide recycling, processes that sustain continual efferocytosis and resolution programming. Defects in these pathways, amplified by proteolytic cleavage of apoptotic cell receptors, dysregulated metabolism, and inflammatory mediators, underlie impaired efferocytosis in atherosclerosis, myocardial infarction, vascular aging, and metabolic diseases. Finally, we discuss emerging concepts, including nonprofessional phagocyte contributions, crosstalk with adaptive immunity, and therapeutic strategies to enhance efferocytosis or preserve receptor integrity. Collectively, these insights redefine efferocytosis as more than a cleanup mechanism, positioning it as a central contributor to attenuating cardiometabolic diseases.Graphical AbstractOpen in ViewerGet full access to this articleView all available purchase options and get full access to this article.Get AccessAlready a Subscriber? Sign in as an individual or via your institutionReferences1.Doran AC, Yurdagul A, Tabas I. Efferocytosis in health and disease. Nat Rev Immunol. 2020;20:254–267. doi: 10.1038/s41577-019-0240-6CrossrefPubMedGoogle Scholar2.Yurdagul A, Doran AC, Cai B, Fredman G, Tabas IA. Mechanisms and consequences of defective efferocytosis in atherosclerosis. Front Cardiovasc Med. 2018;4:86. doi: 10.3389/fcvm.2017.00086CrossrefPubMedGoogle Scholar3.Adkar SS, Leeper NJ. Efferocytosis in atherosclerosis. Nat Rev Cardiol. 2024;21:762–779. doi: 10.1038/s41569-024-01037-7CrossrefPubMedGoogle Scholar4.Wan E, Yeap XY, Dehn S, Terry R, Novak M, Zhang S, Iwata S, Han X, Homma S, Drosatos K, et al. Enhanced efferocytosis of apoptotic cardiomyocytes through myeloid-epithelial-reproductive tyrosine kinase links acute inflammation resolution to cardiac repair after infarction. Circ Res. 2013;113:1004–1012. doi: 10.1161/CIRCRESAHA.113.301198CrossrefPubMedGoogle Scholar5.Arandjelovic S, Ravichandran KS. Phagocytosis of apoptotic cells in homeostasis. Nat Immunol. 2015;16:907–917. doi: 10.1038/ni.3253CrossrefPubMedGoogle Scholar6.Yurdagul A. Metabolic consequences of efferocytosis and its impact on atherosclerosis. Immunometabolism. 2021;3:e210017. doi: 10.20900/immunometab20210017CrossrefPubMedGoogle Scholar7.Moon B, Yang S, Moon H, Lee J, Park D. After cell death: the molecular machinery of efferocytosis. Exp Mol Med. 2023;55:1644–1651. doi: 10.1038/s12276-023-01070-5CrossrefPubMedGoogle Scholar8.Hochreiter-Hufford A, Ravichandran KS. Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion. Cold Spring Harb Perspect Biol. 2013;5:a008748. doi: 10.1101/cshperspect.a008748CrossrefPubMedGoogle Scholar9.Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, Ostankovich M, Sharma P, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009;461:282–286. doi: 10.1038/nature08296CrossrefPubMedGoogle Scholar10.Truman LA, Ford CA, Pasikowska M, Pound JD, Wilkinson SJ, Dumitriu IE, Melville L, Melrose LA, Ogden CA, Nibbs R, et al. CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood. 2008;112:5026–5036. doi: 10.1182/blood-2008-06-162404CrossrefPubMedGoogle Scholar11.Mueller RB, Sheriff A, Gaipl US, Wesselborg S, Lauber K. Attraction of phagocytes by apoptotic cells is mediated by lysophosphatidylcholine. Autoimmunity. 2007;40:342–344. doi: 10.1080/08916930701356911CrossrefPubMedGoogle Scholar12.Gude DR, Alvarez SE, Paugh SW, Mitra P, Yu J, Griffiths R, Barbour SE, Milstien S, Spiegel S. Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a “come-and-get-me” signal. FASEB J. 2008;22:2629–2638. doi: 10.1096/fj.08-107169CrossrefPubMedGoogle Scholar13.Chekeni FB, Elliott MR, Sandilos JK, Walk SF, Kinchen JM, Lazarowski ER, Armstrong AJ, Penuela S, Laird DW, Salvesen GS, et al. Pannexin 1 channels mediate ‘find-me’signal release and membrane permeability during apoptosis. Nature. 2010;467:863–867. doi: 10.1038/nature09413CrossrefPubMedGoogle Scholar14.Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood. 2003;102:1186–1195. doi: 10.1182/blood-2002-12-3775CrossrefPubMedGoogle Scholar15.Murakami N, Yokomizo T, Okuno T, Shimizu T. G2A Is a proton-sensing G-protein-coupled receptor antagonized by lysophosphatidylcholine. J Biol Chem. 2004;279:42484–42491. doi: 10.1074/jbc.M406561200CrossrefGoogle Scholar16.Bena S, Brancaleone V, Wang JM, Perretti M, Flower RJ. Annexin A1 interaction with the FPR2/ALX receptor: identification of distinct domains and downstream associated signaling. J Biol Chem. 2012;287:24690–24697. doi: 10.1074/jbc.M112.377101CrossrefGoogle Scholar17.Kelley SM, Ravichandran KS. Putting the brakes on phagocytosis: “don’t-eat-me” signaling in physiology and disease. EMBO Rep. 2021;22:e52564. doi: 10.15252/embr.202152564CrossrefPubMedGoogle Scholar18.Suzuki J, Denning DP, Imanishi E, Horvitz HR, Nagata S. Xk-related protein 8 and CED-8 promote phosphatidylserine exposure in apoptotic cells. Science. 2013;341:403–406. doi: 10.1126/science.1236758CrossrefPubMedGoogle Scholar19.Suzuki J, Fujii T, Imao T, Ishihara K, Kuba H, Nagata S. Calcium-dependent phospholipid scramblase activity of TMEM16 protein family members. J Biol Chem. 2013;288:13305–13316. doi: 10.1074/jbc.M113.457937CrossrefPubMedGoogle Scholar20.Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123:321–334. doi: 10.1016/j.cell.2005.08.032CrossrefPubMedGoogle Scholar21.Greenberg ME, Sun M, Zhang R, Febbraio M, Silverstein R, Hazen SL. Oxidized phosphatidylserine–CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J Exp Med. 2006;203:2613–2625. doi: 10.1084/jem.20060370CrossrefGoogle Scholar22.Schloesser D, Lindenthal L, Sauer J, Chung KJ, Chavakis T, Griesser E, Baskaran P, Maier-Habelsberger U, Fundel-Clemens K, Schlotthauer I, et al. Senescent cells suppress macrophage-mediated corpse removal via upregulation of the CD47-QPCT/L axis. J Cell Biol. 2022;222:e202207097. doi: 10.1083/jcb.202207097CrossrefPubMedGoogle Scholar23.Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One. 2015;10:e0137345. doi: 10.1371/journal.pone.0137345CrossrefPubMedGoogle Scholar24.Veillette A, Thibaudeau E, Latour S. High expression of inhibitory receptor SHPS-1 and its association with protein-tyrosine phosphatase SHP-1 in macrophages. J Biol Chem. 1998;273:22719–22728. doi: 10.1074/jbc.273.35.22719CrossrefGoogle Scholar25.Fujioka Y, Matozaki T, Noguchi T, Iwamatsu A, Yamao T, Takahashi N, Tsuda M, Takada T, Kasuga M. A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion. Mol Cell Biol. 1996;16:6887–6899. doi: 10.1128/MCB.16.12.6887CrossrefPubMedGoogle Scholar26.Kojima Y, Volkmer JP, McKenna K, Civelek M, Lusis AJ, Miller CL, Direnzo D, Nanda V, Ye J, Connolly AJ, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature. 2016;536:86–90. doi: 10.1038/nature18935CrossrefPubMedGoogle Scholar27.Park D, Tosello-Trampont AC, Elliott MR, Lu M, Haney LB, Ma Z, Klibanov AL, Mandell JW, Ravichandran KS. BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature. 2007;450:430–434. doi: 10.1038/nature06329CrossrefPubMedGoogle Scholar28.McShane L, Tabas I, Lemke G, Kurowska-Stolarska M, Maffia P. TAM receptors in cardiovascular disease. Cardiovasc Res. 2019;115:1286–1295. doi: 10.1093/cvr/cvz100CrossrefPubMedGoogle Scholar29.Penberthy KK, Ravichandran KS. Apoptotic cell recognition receptors and scavenger receptors. Immunol Rev. 2016;269:44–59. doi: 10.1111/imr.12376CrossrefPubMedGoogle Scholar30.Hanayama R, Tanaka M, Miwa K, Shinohara A, Iwamatsu A, Nagata S. Identification of a factor that links apoptotic cells to phagocytes. Nature. 2002;417:182–187. doi: 10.1038/417182aCrossrefPubMedGoogle Scholar31.Nakaya M, Kitano M, Matsuda M, Nagata S. Spatiotemporal activation of Rac1 for engulfment of apoptotic cells. Proc Natl Acad Sci USA. 2008;105:9198–9203. doi: 10.1073/pnas.0803677105CrossrefPubMedGoogle Scholar32.Kim SY, Kim S, Bae DJ, Park SY, Lee GY, Park GM, Kim IS. Coordinated balance of Rac1 and RhoA plays key roles in determining phagocytic appetite. PLoS One. 2017;12:e0174603. doi: 10.1371/journal.pone.0174603CrossrefPubMedGoogle Scholar33.Vieira OV, Bucci C, Harrison RE, Trimble WS, Lanzetti L, Gruenberg J, Schreiber AD, Stahl PD, Grinstein S. Modulation of Rab5 and Rab7 recruitment to phagosomes by phosphatidylinositol 3-kinase. Mol Cell Biol. 2003;23:2501–2514. doi: 10.1128/MCB.23.7.2501-2514.2003CrossrefPubMedGoogle Scholar34.Vanlandingham PA, Ceresa BP. Rab7 regulates late endocytic trafficking downstream of multivesicular body biogenesis and cargo sequestration. J Biol Chem. 2009;284:12110–12124. doi: 10.1074/jbc.M809277200CrossrefGoogle Scholar35.Stroope C, Nettersheim FS, Coon B, Finney AC, Schwartz MA, Ley K, Rom O, Yurdagul A. Dysregulated cellular metabolism in atherosclerosis: mediators and therapeutic opportunities. Nat Metab. 2024;6:617–638. doi: 10.1038/s42255-024-01015-wCrossrefPubMedGoogle Scholar36.Lai SC, Devenish RJ. LC3-associated phagocytosis (LAP): connections with host autophagy. Cells. 2012;1:396–408. doi: 10.3390/cells1030396CrossrefPubMedGoogle Scholar37.Doran AC. Inflammation resolution: implications for atherosclerosis. Circ Res. 2022;130:130–148. doi: 10.1161/CIRCRESAHA.121.319822CrossrefPubMedGoogle Scholar38.Wang Y, Subramanian M, Yurdagul A, Barbosa-Lorenzi VC, Cai B, de Juan-Sanz J, Ryan TA, Nomura M, Maxfield FR, Tabas I. Mitochondrial fission promotes the continued clearance of apoptotic cells by macrophages. Cell. 2017;171:331.e22–345.e22. doi: 10.1016/j.cell.2017.08.041CrossrefGoogle Scholar39.Kidani Y, Bensinger SJ. Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity. Immunol Rev. 2012;249:72–83. doi: 10.1111/j.1600-065X.2012.01153.xCrossrefPubMedGoogle Scholar40.Viaud M, Ivanov S, Vujic N, Duta-Mare M, Aira LE, Barouillet T, Garcia E, Orange F, Dugail I, Hainault I, et al. Lysosomal cholesterol hydrolysis couples efferocytosis to anti-inflammatory oxysterol production. Circ Res. 2018;122:1369–1384. doi: 10.1161/CIRCRESAHA.117.312333CrossrefPubMedGoogle Scholar41.Yvan-Charvet L, Pagler TA, Seimon TA, Thorp E, Welch CL, Witztum JL, Tabas I, Tall AR. ABCA1 and ABCG1 protect against oxidative stress–induced macrophage apoptosis during efferocytosis. Circ Res. 2010;106:1861–1869. doi: 10.1161/CIRCRESAHA.110.217281CrossrefPubMedGoogle Scholar42.Fond AM, Lee CS, Schulman IG, Kiss RS, Ravichandran KS. Apoptotic cells trigger a membrane-initiated pathway to increase ABCA1. J Clin Invest. 2015;125:2748–2758. doi: 10.1172/JCI80300CrossrefPubMedGoogle Scholar43.Yalcinkaya M, Tall AR. Cholesterol crystals as triggers of NLRP3 inflammasome activation in atherosclerosis. Curr Atheroscler Rep. 2025;27:1–9. doi: 10.1007/s11883-025-01323-wCrossrefGoogle Scholar44.Grebe A, Hoss F, Latz E. NLRP3 Inflammasome and the IL-1 pathway in atherosclerosis. Circ Res. 2018;122:1722–1740. doi: 10.1161/CIRCRESAHA.118.311362CrossrefPubMedGoogle Scholar45.Cui D, Thorp E, Li Y, Wang N, Yvan-Charvet L, Tall AR, Tabas I. Pivotal advance: macrophages become resistant to cholesterol-induced death after phagocytosis of apoptotic cells. J Leukoc Biol. 2007;82:1040–1050. doi: 10.1189/jlb.0307192CrossrefPubMedGoogle Scholar46.Patterson MT, Firulyova MM, Xu Y, Hillman H, Bishop C, Zhu A, Hickok GH, Schrank PR, Ronayne CE, Caillot Z, et al. Trem2 promotes foamy macrophage lipid uptake and survival in atherosclerosis. Nat Cardiovasc Res. 2023;2:1015–1031. doi: 10.1038/s44161-023-00354-3CrossrefPubMedGoogle Scholar47.Zernecke A, Erhard F, Weinberger T, Schulz C, Ley K, Saliba AE, Cochain C. Integrated single-cell analysis-based classification of vascular mononuclear phagocytes in mouse and human atherosclerosis. Cardiovasc Res. 2023;119:1676–1689. doi: 10.1093/cvr/cvac161CrossrefPubMedGoogle Scholar48.Piollet M, Porsch F, Rizzo G, Kapser F, Schulz DJ, Kiss MG, Schlepckow K, Morenas-Rodriguez E, Sen MO, Gropper J. TREM2 protects from atherosclerosis by limiting necrotic core formation. Nat Cardiovasc Res. 2024;3:269–282. doi: 10.1038/s44161-024-00429-9CrossrefPubMedGoogle Scholar49.Zhang S, Weinberg S, DeBerge M, Gainullina A, Schipma M, Kinchen JM, Ben-Sahra I, Gius DR, Yvan-Charvet L, Chandel NS, et al. Efferocytosis fuels requirements of fatty acid oxidation and the electron transport chain to polarize macrophages for tissue repair. Cell Metab. 2019;29:443.e5–456.e5. doi: 10.1016/j.cmet.2018.12.004CrossrefGoogle Scholar50.Merlin J, Ivanov S, Dumont A, Sergushichev A, Gall J, Stunault M, Ayrault M, Vaillant N, Castiglione A, Swain A, et al. Non-canonical glutamine transamination sustains efferocytosis by coupling redox buffering to oxidative phosphorylation. Nat Metab. 2021;3:1313–1326. doi: 10.1038/s42255-021-00471-yCrossrefPubMedGoogle Scholar51.Yurdagul A, Subramanian M, Wang X, Crown SB, Ilkayeva OR, Darville L, Kolluru GK, Rymond CC, Gerlach BD, Zheng Z, et al. Macrophage metabolism of apoptotic cell-derived arginine promotes continual efferocytosis and resolution of injury. Cell Metab. 2020;31:518.e10–533.e10. doi: 10.1016/j.cmet.2020.01.001CrossrefGoogle Scholar52.Sukka SR, Ampomah PB, Darville LN, Ngai D, Wang X, Kuriakose G, Xiao Y, Shi J, Koomen JM, McCusker RH, et al. Efferocytosis drives a tryptophan metabolism pathway in macrophages to promote tissue resolution. Nat Metab. 2024;6:1736–1755. doi: 10.1038/s42255-024-01115-7CrossrefPubMedGoogle Scholar53.Ampomah PB, Cai B, Sukka SR, Gerlach BD, Yurdagul A, Wang X, Kuriakose G, Darville LN, Sun Y, Sidoli S, et al. Macrophages use apoptotic cell-derived methionine and DNMT3A during efferocytosis to promote tissue resolution. Nat Metab. 2022;4:444–457. doi: 10.1038/s42255-022-00551-7CrossrefPubMedGoogle Scholar54.Gerlach BD, Ampomah PB, Yurdagul A, Liu C, Lauring MC, Wang X, Kasikara C, Kong N, Shi J, Tao W, et al. Efferocytosis induces macrophage proliferation to help resolve tissue injury. Cell Metab. 2021;33:2445.e8–2463.e8. doi: 10.1016/j.cmet.2021.10.015CrossrefGoogle Scholar55.Soto-Heredero G, Gómez de Las Heras MM, Gabandé-Rodríguez E, Oller J, Mittelbrunn M. Glycolysis–a key player in the inflammatory response. FEBS J. 2020;287:3350–3369. doi: 10.1111/febs.15327CrossrefPubMedGoogle Scholar56.Schilperoort M, Ngai D, Katerelos M, Power DA, Tabas I. PFKFB2-mediated glycolysis promotes lactate-driven continual efferocytosis by macrophages. Nat Metab. 2023;5:431–444. doi: 10.1038/s42255-023-00736-8CrossrefPubMedGoogle Scholar57.Morioka S, Perry JS, Raymond MH, Medina CB, Zhu Y, Zhao L, Serbulea V, Onengut-Gumuscu S, Leitinger N, Kucenas S, et al. Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release. Nature. 2018;563:714–718. doi: 10.1038/s41586-018-0735-5CrossrefPubMedGoogle Scholar58.Ngai D, Schilperoort M, Tabas I. Efferocytosis-induced lactate enables the proliferation of pro-resolving macrophages to mediate tissue repair. Nat Metab. 2023;5:2206–2219. doi: 10.1038/s42255-023-00921-9CrossrefPubMedGoogle Scholar59.Wang YT, Trzeciak AJ, Rojas WS, Saavedra P, Chen YT, Chirayil R, Etchegaray JI, Lucas CD, Puleston DJ, Keshari KR, et al. Metabolic adaptation supports enhanced macrophage efferocytosis in limited-oxygen environments. Cell Metab. 2023;35:316.e6–331.e6. doi: 10.1016/j.cmet.2022.12.005CrossrefGoogle Scholar60.Thorp E, Vaisar T, Subramanian M, Mautner L, Blobel C, Tabas I. Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein Kinase Cδ, and p38 mitogen-activated protein kinase (MAPK). J Biol Chem. 2011;286:33335–33344. doi: 10.1074/jbc.M111.263020CrossrefPubMedGoogle Scholar61.Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM, Graham DK. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood. 2007;109:1026–1033. doi: 10.1182/blood-2006-05-021634CrossrefPubMedGoogle Scholar62.Driscoll WS, Vaisar T, Tang J, Wilson CL, Raines EW. Macrophage ADAM17 deficiency augments CD36-dependent apoptotic cell uptake and the linked anti-inflammatory phenotype. Circ Res. 2013;113:52–61. doi: 10.1161/CIRCRESAHA.112.300683CrossrefPubMedGoogle Scholar63.Handberg A, Levin K, Højlund K, Beck-Nielsen H. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation. 2006;114:1169–1176. doi: 10.1161/CIRCULATIONAHA.106.626135CrossrefPubMedGoogle Scholar64.Handberg A, Skjelland M, Michelsen AE, Sagen EL, Krohg-Sørensen K, Russell D, Dahl A, Ueland T, Øie E, Aukrust P, et al. Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability. Stroke. 2008;39:3092–3095. doi: 10.1161/STROKEAHA.108.517128CrossrefPubMedGoogle Scholar65.García-Monzón C, Lo Iacono O, Crespo J, Romero-Gómez M, García-Samaniego J, Fernández-Bermejo M, Domínguez-Díez A, Rodríguez De Cía J, Sáez A, Porrero JL, et al. Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease. Eur J Clin Invest. 2014;44:65–73. doi: 10.1111/eci.12192CrossrefPubMedGoogle Scholar66.Liu G, Wang J, Park YJ, Tsuruta Y, Lorne EF, Zhao X, Abraham E. High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J Immunol. 2008;181:4240–4246. doi: 10.4049/jimmunol.181.6.4240CrossrefGoogle Scholar67.Wang Y, Zhang W, Xu Y, Wu D, Gao Z, Zhou J, Qian H, He B, Wang G. Extracellular HMGB1 impairs macrophage-mediated efferocytosis by suppressing the Rab43-controlled cell surface transport of CD91. Front Immunol. 2022;13:767630. doi: 10.3389/fimmu.2022.767630CrossrefPubMedGoogle Scholar68.Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity. 2008;29:21–32. doi: 10.1016/j.immuni.2008.05.013CrossrefPubMedGoogle Scholar69.Gilchrist SE, Goudarzi S, Hafizi S. Gas6 inhibits toll-like receptor-mediated inflammatory pathways in mouse microglia via axl and mer. Front Cell Neurosci. 2020;14:576650. doi: 10.3389/fncel.2020.576650CrossrefPubMedGoogle Scholar70.Seneviratne AN, Edsfeldt A, Cole JE, Kassiteridi C, Swart M, Park I, Green P, Khoyratty T, Saliba D, Goddard ME, et al. Interferon regulatory factor 5 controls necrotic core formation in atherosclerotic lesions by impairing efferocytosis. Circulation. 2017;136:1140–1154. doi: 10.1161/CIRCULATIONAHA.117.027844CrossrefPubMedGoogle Scholar71.Lv JJ, Wang H, Zhang C, Zhang TJ, Wei HL, Liu ZK, Ma YH, Yang Z, He Q, Wang LJ, et al. CD147 sparks atherosclerosis by driving M1 phenotype and impairing efferocytosis. Circ Res. 2024;134:165–185. doi: 10.1161/CIRCRESAHA.123.323223CrossrefPubMedGoogle Scholar72.Ait-Oufella H, Kinugawa K, Zoll J, Simon T, Boddaert J, Heeneman S, Blanc-Brude O, Barateau V, Potteaux S, Merval R, et al. Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation. 2007;115:2168–2177. doi: 10.1161/CIRCULATIONAHA.106.662080CrossrefPubMedGoogle Scholar73.Kojima Y, Downing K, Kundu R, Miller C, Dewey F, Lancero H, Raaz U, Perisic L, Hedin U, Schadt E, et al. Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis. J Clin Invest. 2014;124:1083–1097. doi: 10.1172/JCI70391CrossrefPubMedGoogle Scholar74.Overton CD, Yancey PG, Major AS, Linton MF, Fazio S. Deletion of macrophage LDL receptor–related protein increases atherogenesis in the mouse. Circ Res. 2007;100:670–677. doi: 10.1161/01.RES.0000260204.40510.aaCrossrefPubMedGoogle Scholar75.Yancey PG, Blakemore J, Ding L, Fan D, Overton CD, Zhang Y, Linton MF, Fazio S. Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation. Arterioscler Thromb Vasc Biol. 2010;30:787–795. doi: 10.1161/ATVBAHA.109.202051CrossrefPubMedGoogle Scholar76.Nanda V, Downing KP, Ye J, Xiao S, Kojima Y, Spin JM, DiRenzo D, Nead KT, Connolly AJ, Dandona S, et al. CDKN2B regulates TGFβ signaling and smooth muscle cell investment of hypoxic neovessels. Circ Res. 2016;118:230–240. doi: 10.1161/CIRCRESAHA.115.307906CrossrefPubMedGoogle Scholar77.Kasikara C, Schilperoort M, Gerlach B, Xue C, Wang X, Zheng Z, Kuriakose G, Dorweiler B, Zhang H, Fredman G, et al. Deficiency of macrophage PHACTR1 impairs efferocytosis and promotes atherosclerotic plaque necrosis. J Clin Invest. 2021;131:e145275. doi: 10.1172/JCI145275CrossrefPubMedGoogle Scholar78.Silva-Sanchez A, Meza-Perez S, Liu M, Stone SL, Flores-Romo L, Ubil E, Lund FE, Rosenberg AF, Randall TD. Activation of regulatory dendritic cells by Mertk coincides with a temporal wave of apoptosis in neonatal lungs. Sci Immunol. 2023;8:eadc9081. doi: 10.1126/sciimmunol.adc9081CrossrefPubMedGoogle Scholar79.Kojima Y, Werner N, Ye J, Nanda V, Tsao N, Wang Y, Flores AM, Miller CL, Weissman I, Deng H, et al. Proefferocytic therapy promotes transforming growth factor-β signaling and prevents aneurysm formation. Circulation. 2018;137:750–753. doi: 10.1161/CIRCULATIONAHA.117.030389CrossrefPubMedGoogle Scholar80.Singla B, Lin HP, Ahn W, Xu J, Ma Q, Sghayyer M, Dong K, Cherian-Shaw M, Zhou J, Huo Y, et al. Loss of myeloid cell-specific SIRPα, but not CD47, attenuates inflammation and suppresses atherosclerosis. Cardiovasc Res. 2022;118:3097–3111. doi: 10.1093/cvr/cvab369CrossrefPubMedGoogle Scholar81.Jarr KU, Ye J, Kojima Y, Ye Z, Gao H, Schmid S, Luo L, Baylis RA, Lotfi M, Lopez N, et al. The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis. Nat Cardiovasc Res. 2022;1:253–262. doi: 10.1038/s44161-022-00023-xCrossrefPubMedGoogle Scholar82.Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010;30:1282–1292. doi: 10.1161/ATVBAHA.108.179739CrossrefPubMedGoogle Scholar83.Heidt T, Courties G, Dutta P, Sager HB, Sebas M, Iwamoto Y, Sun Y, Da Silva N, Panizzi P, Van Der Laan AM, et al. Differential contribution of monocytes to heart macrophages in steady-state and after myocardial infarction. Circ Res. 2014;115:284–295. doi: 10.1161/CIRCRESAHA.115.303567CrossrefPubMedGoogle Scholar84.Bajpai G, Bredemeyer A, Li W, Zaitsev K, Koenig AL, Lokshina I, Mohan J, Ivey B, Hsiao HM, Weinheimer C, et al. Tissue resident CCR2− and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. Circ Res. 2019;124:263–278. doi: 10.1161/CIRCRESAHA.118.314028CrossrefPubMedGoogle Scholar85.Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51:600–606. doi: 10.1016/j.yjmcc.2010.10.033CrossrefPubMedGoogle Scholar86.Francis Stuart SD, De Jesus NM, Lindsey ML, Ripplinger CM. The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction. J Mol Cell Cardiol. 2016;91:114–122. doi: 10.1016/j.yjmcc.2015.12.024CrossrefPubMedGoogle Scholar87.Glinton KE, Ma W, Lantz C, Grigoryeva LS, DeBerge M, Liu X, Febbraio M, Kahn M, Oliver G, Thorp EB. Macrophage-produced VEGFC is induced by efferocytosis to ameliorate cardiac injury and inflammation. J Clin Invest. 2022;132:e140685. doi: 10.1172/JCI140685CrossrefPubMedGoogle Scholar88.DeBerge M, Yeap XY, Dehn S, Zhang S, Grigoryeva L, Misener S, Procissi D, Zhou X, Lee DC, Muller WA, et al. MerTK cleavage on resident cardiac macrophages compromises repair after myocardial ischemia reperfusion injury. Circ Res. 2017;121:930–940. doi: 10.1161/CIRCRESAHA.117.311327CrossrefPubMedGoogle Scholar89.Zhang S, Yeap XY, Grigoryeva L, Dehn S, DeBerge M, Tye M, Rostlund E, Schrijvers D, Zhang ZJ, Sumagin R, et al. Cardiomyocytes induce macrophage receptor shedding to suppress phagocytosis. J Mol Cell Cardiol. 2015;87:171–179. doi: 10.1016/j.yjmcc.2015.08.009CrossrefPubMedGoogle Scholar90.Zhang S, Yeap XY, DeBerge M, Naresh NK, Wang K, Jiang Z, Wilcox JE, White SM, Morrow JP, Burridge PW, et al. Acute CD47 blockade during ischemic myocardial reperfusion enhances phagocytosis-associated cardiac repair. JACC Basic Transl Sci. 2017;2:386–397. doi: 10.1016/j.jacbts.2017.03.013CrossrefPubMedGoogle Scholar91.Maier JA, Andrés V, Castiglioni S, Giudici A, Lau ES, Nemcsik J, Seta F, Zaninotto P, Catalano M, Hamburg NM. Aging and vascular disease: a multidisciplinary overview. J Clin Med. 2023;12:5512. doi: 10.3390/jcm12175512CrossrefPubMedGoogle Scholar92.Rymut N, Heinz J, Sadhu S, Hosseini Z, Riley CO, Marinello M, Maloney J, MacNamara KC, Spite M, Fredman G. Resolvin D1 promotes efferocytosis in aging by limiting senescent cell-induced MerTK cleavage. FASEB J. 2020;34:597–609. doi: 10.1096/fj.201902126RCrossrefPubMedGoogle Scholar93.Han Y, Kim SY. Endothelial senescence in vascular diseases: current understanding and future opportunities in senotherapeutics. Exp Mol Med. 2023;55:1–12. doi: 10.1038/s12276-022-00906-wCrossrefPubMedGoogle Scholar94.Incalza MA, D’Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018;100:1–19. doi: 10.1016/j.vph.2017.05.005CrossrefPubMedGoogle Scholar95.Yamashita A, Noma T, Nakazawa A, Saito S, Fujioka K, Zempo N, Esato K. Enhanced expression of matrix metalloproteinase-9 in abdominal aortic aneurysms. World J Surg. 2001;25:259–265. doi: 10.1007/s002680020062CrossrefPubMedGoogle Scholar96.Apovian CM, Bigornia S, Mott M, Meyers MR, Ulloor J, Gagua M, McDonnell M, Hess D, Joseph L, Gokce N. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol. 2008;28:1654–1659. doi: 10.1161/ATVBAHA.108.170316CrossrefPubMedGoogle Scholar97.Mao QY, He SY, Hu QY, Lu Y, Niu YX, Li XY, Zhang HM, Qin L, Su Q. Advanced glycation end products (AGEs) inhibit macrophage efferocytosis of apoptotic β cells through binding to the receptor for AGEs. J Immunol. 2022;208:1204–1213. doi: 10.4049/jimmunol.2100695CrossrefGoogle Scholar98.Liebold I, Meyer S, Heine M, Kuhl A, Witt J, Eissing L, Fischer A, Koop A, Kluwe J, Schulze Zur Wiesch J, et al. TREM2 regulates the removal of apoptotic cells and inflammatory processes during the progression of NAFLD. Cells. 2023;12:341. doi: 10.3390/cells12030341CrossrefPubMedGoogle Scholar99.Shi H, Wang X, Sloas C, Gerlach B, Yurdagul A, Moore MP, Jung EJ, Mirshahi F, Ronzoni L, Sanyal AJ, et al. Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction-associated steatohepatitis. Sci Transl Med. 2025;17:eadv2106. doi: 10.1126/scitranslmed.adv2106CrossrefPubMedGoogle Scholar100.Shi H, Moore MP, Wang X, Tabas I. Efferocytosis in liver disease. JHEP Rep. 2024;6:100960. doi: 10.1016/j.jhepr.2023.100960CrossrefPubMedGoogle Scholar101.Xu Y, Hillman H, Chang M, Barrow F, Ivanov S, Revelo XS, Williams JW. Identification of conserved and tissue-restricted transcriptional profiles for lipid associated macrophages. Commun Biol. 2025;8:953. doi: 10.1038/s42003-025-08387-zCrossrefPubMedGoogle Scholar102.Han CZ, Juncadella IJ, Kinchen JM, Buckley MW, Klibanov AL, Dryden K, Onengut-Gumuscu S, Erdbrügger U, Turner SD, Shim YM, et al. Macrophages redirect phagocytosis by non-professional phagocytes and influence inflammation. Nature. 2016;539:570–574. doi: 10.1038/nature20141CrossrefPubMedGoogle Scholar103.Bennett MR, Gibson DF, Schwartz SM, Tait JF. Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine. Circ Res. 1995;77:1136–1142. doi: 10.1161/01.res.77.6.1136CrossrefPubMedGoogle Scholar104.Clarke MCH, Talib S, Figg NL, Bennett MR. Vascular smooth muscle cell apoptosis induces interleukin-1–directed inflammation: effects of hyperlipidemia-mediated inhibition of phagocytosis. Circ Res. 2010;106:363–372. doi: 10.1161/CIRCRESAHA.109.208389CrossrefPubMedGoogle Scholar105.Nakaya M, Watari K, Tajima M, Nakaya T, Matsuda S, Ohara H, Nishihara H, Yamaguchi H, Hashimoto A, Nishida M, et al. Cardiac myofibroblast engulfment of dead cells facilitates recovery after myocardial infarction. J Clin Invest. 2017;127:383–401. doi: 10.1172/JCI83822CrossrefPubMedGoogle Scholar106.Romana-Souza B, Chen L, Leonardo TR, Chen Z, DiPietro LA. Dermal fibroblast phagocytosis of apoptotic cells: a novel pathway for wound resolution. FASEB J. 2021;35:e21443. doi: 10.1096/fj.202002078rCrossrefPubMedGoogle Scholar107.Yoon H, Choi SI, Kim EK. Uptake of cell debris and enhanced expression of inflammatory factors in response to dead cells in corneal fibroblast cells. Exp Eye Res. 2020;194:108017. doi: 10.1016/j.exer.2020.108017CrossrefPubMedGoogle Scholar108.Dini L, Pagliara P, Carlà EC. Phagocytosis of apoptotic cells by liver: a morphological study. Microsc Res Tech. 2002;57:530–540. doi: 10.1002/jemt.10107CrossrefPubMedGoogle Scholar109.Hess KL, Tudor KS, Johnson JD, Osati-Ashtiani F, Askew DS, Cook-Mills JM. Human and murine high endothelial venule cells phagocytose apoptotic leukocytes. Exp Cell Res. 1997;236:404–411. doi: 10.1006/excr.1997.3745CrossrefPubMedGoogle Scholar110.Kirsch T, Woywodt A, Beese M, Wyss K, Park JK, Erdbruegger U, Hertel B, Haller H, Haubitz M. Engulfment of apoptotic cells by microvascular endothelial cells induces proinflammatory responses. Blood. 2007;109:2854–2862. doi: 10.1182/blood-2006-06-026187CrossrefPubMedGoogle Scholar111.Chen Q, Stone PR, McCowan LME, Chamley LW. Phagocytosis of necrotic but not apoptotic trophoblasts induces endothelial cell activation. Hypertension. 2006;47:116–121. doi: 10.1161/01.HYP.0000196731.56062.7cCrossrefPubMedGoogle Scholar112.Wu J, Liu S, Banerjee O, Shi H, Xue B, Ding Z. Disturbed flow impairs MerTK-mediated efferocytosis in aortic endothelial cells during atherosclerosis. Theranostics. 2024;14:2427–2441. doi: 10.7150/thno.93036CrossrefPubMedGoogle Scholar113.Liu S, Wu J, Banerjee O, Xue B, Shi H, Ding Z. Big data analytics and scRNA-seq in human aortic aneurysms and dissections: role of endothelial MerTK. Theranostics. 2025;15:202–215. doi: 10.7150/thno.103851CrossrefPubMedGoogle Scholar114.Iyoda T, Shimoyama S, Liu K, Omatsu Y, Akiyama Y, Maeda Y, Takahara K, Steinman RM, Inaba K. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med. 2002;195:1289–1302. doi: 10.1084/jem.20020161CrossrefGoogle Scholar115.Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392:86–89. doi: 10.1038/32183CrossrefPubMedGoogle Scholar116.Morelli AE, Larregina AT, Shufesky WJ, Zahorchak AF, Logar AJ, Papworth GD, Wang Z, Watkins SC, Falo LD, Thomson AW. Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood. 2003;101:611–620. doi: 10.1182/blood-2002-06-1769CrossrefPubMedGoogle Scholar117.Krispin A, Bledi Y, Atallah M, Trahtemberg U, Verbovetski I, Nahari E, Zelig O, Linial M, Mevorach D. Apoptotic cell thrombospondin-1 and heparin-binding domain lead to dendritic-cell phagocytic and tolerizing states. Blood. 2006;108:3580–3589. doi: 10.1182/blood-2006-03-013334CrossrefPubMedGoogle Scholar118.Kool M, van Loo G, Waelput W, De Prijck S, Muskens F, Sze M, van Praet J, Branco-Madeira F, Janssens S, Reizis B, et al. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity. 2011;35:82–96. doi: 10.1016/j.immuni.2011.05.013CrossrefPubMedGoogle Scholar119.Chen Z, Moyana T, Saxena A, Warrington R, Jia Z, Xiang J. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer. 2001;93:539–548. doi: 10.1002/ijc.1365CrossrefPubMedGoogle Scholar120.Torchinsky MB, Garaude J, Martin AP, Blander JM. Innate immune recognition of infected apoptotic cells directs TH17 cell differentiation. Nature. 2009;458:78–82. doi: 10.1038/nature07781CrossrefPubMedGoogle Scholar121.Wigren M, Rattik S, Yao Mattisson I, Tomas L, Grönberg C, Söderberg I, Alm R, Sundius L, Ljungcrantz I, Björkbacka H, et al. Lack of ability to present antigens on major histocompatibility complex class II molecules aggravates atherosclerosis in ApoE−/− mice. Circulation. 2019;139:2554–2566. doi: 10.1161/CIRCULATIONAHA.118.039288CrossrefPubMedGoogle Scholar122.Ngai D, Sukka SR, Tabas I. Crosstalk between efferocytic myeloid cells and T-cells and its relevance to atherosclerosis. Front Immunol. 2024;15:1403150. doi: 10.3389/fimmu.2024.1403150CrossrefPubMedGoogle Scholar123.Sharma M, Schlegel MP, Afonso MS, Brown EJ, Rahman K, Weinstock A, Sansbury BE, Corr EM, van Solingen C, Koelwyn GJ, et al. Regulatory T cells license macrophage pro-resolving functions during atherosclerosis regression. Circ Res. 2020;127:335–353. doi: 10.1161/CIRCRESAHA.119.316461CrossrefPubMedGoogle Scholar124.Proto JD, Doran AC, Gusarova G, Yurdagul A, Sozen E, Subramanian M, Islam MN, Rymond CC, Du J, Hook J, et al. Regulatory T cells promote macrophage efferocytosis during inflammation resolution. Immunity. 2018;49:666.e6–677.e6. doi: 10.1016/j.immuni.2018.07.015CrossrefGoogle Scholar125.Morimoto K, Janssen WJ, Fessler MB, McPhillips KA, Borges VM, Bowler RP, Xiao YQ, Kench JA, Henson PM, Vandivier RW. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol. 2006;176:7657–7665. doi: 10.4049/jimmunol.176.12.7657CrossrefGoogle Scholar126.Zhang Y, Wang Y, Zhou D, Zhang LS, Deng FX, Shu S, Wang LJ, Wu Y, Guo N, Zhou J, et al. Angiotensin II deteriorates advanced atherosclerosis by promoting MerTK cleavage and impairing efferocytosis through the AT1R/ROS/p38 MAPK/ADAM17 pathway. Am J Physiol Cell Physiol. 2019;317:C776–C787. doi: 10.1152/ajpcell.00145.2019CrossrefPubMedGoogle Scholar127.Cai B, Thorp EB, Doran AC, Sansbury BE, Daemen MJ, Dorweiler B, Spite M, Fredman G, Tabas I. MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis. J Clin Invest. 2017;127:564–568. doi: 10.1172/JCI90520CrossrefPubMedGoogle Scholar128.Seeley EH, Liu Z, Yuan S, Stroope C, Cockerham E, Rashdan NA, Delgadillo LF, Finney AC, Kumar D, Das S, et al. Spatially resolved metabolites in stable and unstable human atherosclerotic plaques identified by mass spectrometry imaging. Arterioscler Thromb Vasc Biol. 2023;43:1626–1635. doi: 10.1161/ATVBAHA.122.318684CrossrefPubMedGoogle Scholar129.Gastanadui MG, Margaroli C, Litovsky S, Richter RP, Wang D, Xing D, Wells JM, Gaggar A, Nanda V, Patel RP, et al. Spatial transcriptomic approach to understanding coronary atherosclerotic plaque stability. Arterioscler Thromb Vasc Biol. 2024;44:e264–e276. doi: 10.1161/ATVBAHA.123.320330CrossrefPubMedGoogle Scholar130.Sun J, Singh P, Shami A, Kluza E, Pan M, Djordjevic D, Michaelsen NB, Kennback C, van der Wel NN, Orho-Melander M, et al. Spatial transcriptional mapping reveals site-specific pathways underlying human atherosclerotic plaque rupture. J Am Coll Cardiol. 2023;81:2213–2227. doi: 10.1016/j.jacc.2023.04.008CrossrefPubMedGoogle ScholarShow all references
eLetterseLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article
Information & AuthorsInformationAuthorsInformationPublished In
Arteriosclerosis, Thrombosis, and Vascular BiologyVolume 46 • Number 2 • February 2026Page: e323211PubMed: 41410050Copyright© 2025 American Heart Association, Inc.VersionsYou are viewing the most recent version of this article.18 December 2025: Ahead of PrintHistoryPublished online: 18 December 2025Published in print: February 2026PermissionsRequest permissions for this article.Request permissionsKeywordsapoptosisefferocytosisinflammationmetabolic reprogrammingphagocytesSubjectsCell Signaling/Signal TransductionCellular ReprogrammingInflammationMetabolismVascular BiologyAuthorsAffiliationsExpand AllRajan Pandit*Department of Molecular and Cellular Physiology (R.P., A.Y.), Louisiana State University Health Sciences Center at Shreveport.View all articles by this authorHannah Hillman* https://orcid.org/0009-0002-5448-3143Department of Integrative Biology and Physiology, Center for Immunology, University of Minnesota, Minneapolis (H.H., J.W.W.).View all articles by this authorJesse W. Williams https://orcid.org/0000-0003-3815-0891Department of Integrative Biology and Physiology, Center for Immunology, University of Minnesota, Minneapolis (H.H., J.W.W.).View all articles by this authorArif Yurdagul Jr https://orcid.org/0000-0002-7613-6313 arif.yurdagul@lsuhs.eduDepartment of Molecular and Cellular Physiology (R.P., A.Y.), Louisiana State University Health Sciences Center at Shreveport.Department of Pathology and Translational Pathobiology (A.Y.), Louisiana State University Health Sciences Center at Shreveport.View all articles by this authorNotesATVB in Focus: Efferocytosis in Cardiovascular Biology and DiseasesSeries Editor: Hanrui Zhang*R. Pandit and H. Hillman contributed equally.For Sources of Funding and Disclosures, see page 298–299.Correspondence to: Arif Yurdagul Jr, PhD, Department of Molecular and Cellular Physiology and the Department of Pathology and Translational Pathobiology, LSU Health Sciences Center at Shreveport, 1501 Kings Hwy, BRI F4-22, Shreveport, LA 71130. Email arif.yurdagul@lsuhs.eduDisclosuresNone.Sources of FundingThis work was supported by the following awards: an American Heart Association predoctoral fellowship 25PRE1361476 (H. Hillman), an National Institutes of Health National Heart, Lung, and Blood Institute F31 predoctoral fellowship 1F31HL182131-01 (H. Hillman), a Center for Cardiovascular Diseases and Sciences Predoctoral Fellowship (R. Pandit), National Institutes of Health R01AI165553 (J.W. Williams), R01HL166843 (J.W. Williams), R01HL167758 (A. Yurdagul Jr), and R01HL180481 (A. Yurdagul Jr), and the National Science Foundation award 2537597 (A. Yurdagul Jr).Metrics & CitationsMetricsCitationsMetrics
Article MetricsView all metricsDownloadsCitationsNo data available.050100Dec 2025Jan 20262300TotalFirst 90 DaysTotal number of
downloads
See more details
Posted by 3 X users
On 1 Facebook pages
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Please select your download format:
RIS (ProCite, Reference Manager)
EndNote
BibTex
Medlars
RefWorks
Direct Import
FiguresOpen all in viewerGo to FigureOpen in ViewerTablesMediaShareShareShare article linkhttps://www.ahajournals.org/doi/pdf/10.1161/ATVBAHA.125.323211Copy LinkCopied!Copying failed.ShareFacebookLinkedInX (formerly Twitter)emailWeChatBlueskyGet AccessGet Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login
Institutional Login
Email
Password
Forgot your password? Reset it
here
Keep me logged in
Login
Don’t have an account? Register
here
Save for later
Item saved, go to cart
Purchase Options
Purchase this article to access the full text.
Purchase access to this article for 24 hours
More Than a Cleanup Crew: The Expanding Biology of Efferocytosis
Arteriosclerosis, Thrombosis, and Vascular Biology
Vol. 46
No. 2
pp. e323501-
USD
$35.00
Add to Cart
Checkout
Purchase access to this journal for 24 hours
Arteriosclerosis, Thrombosis, and Vascular Biology
Vol. 46
No. 2
pp. e323501-
USD
$40.00
Add to Cart
Checkout
Restore your content access
Enter your email address to restore your content access:
Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.
ReferencesReferencesReferences1.Doran AC, Yurdagul A, Tabas I. Efferocytosis in health and disease. Nat Rev Immunol. 2020;20:254–267. doi: 10.1038/s41577-019-0240-6CrossrefPubMedGoogle Scholar2.Yurdagul A, Doran AC, Cai B, Fredman G, Tabas IA. Mechanisms and consequences of defective efferocytosis in atherosclerosis. Front Cardiovasc Med. 2018;4:86. doi: 10.3389/fcvm.2017.00086CrossrefPubMedGoogle Scholar3.Adkar SS, Leeper NJ. Efferocytosis in atherosclerosis. Nat Rev Cardiol. 2024;21:762–779. doi: 10.1038/s41569-024-01037-7CrossrefPubMedGoogle Scholar4.Wan E, Yeap XY, Dehn S, Terry R, Novak M, Zhang S, Iwata S, Han X, Homma S, Drosatos K, et al. Enhanced efferocytosis of apoptotic cardiomyocytes through myeloid-epithelial-reproductive tyrosine kinase links acute inflammation resolution to cardiac repair after infarction. Circ Res. 2013;113:1004–1012. doi: 10.1161/CIRCRESAHA.113.301198CrossrefPubMedGoogle Scholar5.Arandjelovic S, Ravichandran KS. Phagocytosis of apoptotic cells in homeostasis. Nat Immunol. 2015;16:907–917. doi: 10.1038/ni.3253CrossrefPubMedGoogle Scholar6.Yurdagul A. Metabolic consequences of efferocytosis and its impact on atherosclerosis. Immunometabolism. 2021;3:e210017. doi: 10.20900/immunometab20210017CrossrefPubMedGoogle Scholar7.Moon B, Yang S, Moon H, Lee J, Park D. After cell death: the molecular machinery of efferocytosis. Exp Mol Med. 2023;55:1644–1651. doi: 10.1038/s12276-023-01070-5CrossrefPubMedGoogle Scholar8.Hochreiter-Hufford A, Ravichandran KS. Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion. Cold Spring Harb Perspect Biol. 2013;5:a008748. doi: 10.1101/cshperspect.a008748CrossrefPubMedGoogle Scholar9.Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, Ostankovich M, Sharma P, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009;461:282–286. doi: 10.1038/nature08296CrossrefPubMedGoogle Scholar10.Truman LA, Ford CA, Pasikowska M, Pound JD, Wilkinson SJ, Dumitriu IE, Melville L, Melrose LA, Ogden CA, Nibbs R, et al. CX3CL1/fractalkine is released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood. 2008;112:5026–5036. doi: 10.1182/blood-2008-06-162404CrossrefPubMedGoogle Scholar11.Mueller RB, Sheriff A, Gaipl US, Wesselborg S, Lauber K. Attraction of phagocytes by apoptotic cells is mediated by lysophosphatidylcholine. Autoimmunity. 2007;40:342–344. doi: 10.1080/08916930701356911CrossrefPubMedGoogle Scholar12.Gude DR, Alvarez SE, Paugh SW, Mitra P, Yu J, Griffiths R, Barbour SE, Milstien S, Spiegel S. Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a “come-and-get-me” signal. FASEB J. 2008;22:2629–2638. doi: 10.1096/fj.08-107169CrossrefPubMedGoogle Scholar13.Chekeni FB, Elliott MR, Sandilos JK, Walk SF, Kinchen JM, Lazarowski ER, Armstrong AJ, Penuela S, Laird DW, Salvesen GS, et al. Pannexin 1 channels mediate ‘find-me’signal release and membrane permeability during apoptosis. Nature. 2010;467:863–867. doi: 10.1038/nature09413CrossrefPubMedGoogle Scholar14.Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood. 2003;102:1186–1195. doi: 10.1182/blood-2002-12-3775CrossrefPubMedGoogle Scholar15.Murakami N, Yokomizo T, Okuno T, Shimizu T. G2A Is a proton-sensing G-protein-coupled receptor antagonized by lysophosphatidylcholine. J Biol Chem. 2004;279:42484–42491. doi: 10.1074/jbc.M406561200CrossrefGoogle Scholar16.Bena S, Brancaleone V, Wang JM, Perretti M, Flower RJ. Annexin A1 interaction with the FPR2/ALX receptor: identification of distinct domains and downstream associated signaling. J Biol Chem. 2012;287:24690–24697. doi: 10.1074/jbc.M112.377101CrossrefGoogle Scholar17.Kelley SM, Ravichandran KS. Putting the brakes on phagocytosis: “don’t-eat-me” signaling in physiology and disease. EMBO Rep. 2021;22:e52564. doi: 10.15252/embr.202152564CrossrefPubMedGoogle Scholar18.Suzuki J, Denning DP, Imanishi E, Horvitz HR, Nagata S. Xk-related protein 8 and CED-8 promote phosphatidylserine exposure in apoptotic cells. Science. 2013;341:403–406. doi: 10.1126/science.1236758CrossrefPubMedGoogle Scholar19.Suzuki J, Fujii T, Imao T, Ishihara K, Kuba H, Nagata S. Calcium-dependent phospholipid scramblase activity of TMEM16 protein family members. J Biol Chem. 2013;288:13305–13316. doi: 10.1074/jbc.M113.457937CrossrefPubMedGoogle Scholar20.Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123:321–334. doi: 10.1016/j.cell.2005.08.032CrossrefPubMedGoogle Scholar21.Greenberg ME, Sun M, Zhang R, Febbraio M, Silverstein R, Hazen SL. Oxidized phosphatidylserine–CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J Exp Med. 2006;203:2613–2625. doi: 10.1084/jem.20060370CrossrefGoogle Scholar22.Schloesser D, Lindenthal L, Sauer J, Chung KJ, Chavakis T, Griesser E, Baskaran P, Maier-Habelsberger U, Fundel-Clemens K, Schlotthauer I, et al. Senescent cells suppress macrophage-mediated corpse removal via upregulation of the CD47-QPCT/L axis. J Cell Biol. 2022;222:e202207097. doi: 10.1083/jcb.202207097CrossrefPubMedGoogle Scholar23.Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One. 2015;10:e0137345. doi: 10.1371/journal.pone.0137345CrossrefPubMedGoogle Scholar24.Veillette A, Thibaudeau E, Latour S. High expression of inhibitory receptor SHPS-1 and its association with protein-tyrosine phosphatase SHP-1 in macrophages. J Biol Chem. 1998;273:22719–22728. doi: 10.1074/jbc.273.35.22719CrossrefGoogle Scholar25.Fujioka Y, Matozaki T, Noguchi T, Iwamatsu A, Yamao T, Takahashi N, Tsuda M, Takada T, Kasuga M. A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion. Mol Cell Biol. 1996;16:6887–6899. doi: 10.1128/MCB.16.12.6887CrossrefPubMedGoogle Scholar26.Kojima Y, Volkmer JP, McKenna K, Civelek M, Lusis AJ, Miller CL, Direnzo D, Nanda V, Ye J, Connolly AJ, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature. 2016;536:86–90. doi: 10.1038/nature18935CrossrefPubMedGoogle Scholar27.Park D, Tosello-Trampont AC, Elliott MR, Lu M, Haney LB, Ma Z, Klibanov AL, Mandell JW, Ravichandran KS. BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature. 2007;450:430–434. doi: 10.1038/nature06329CrossrefPubMedGoogle Scholar28.McShane L, Tabas I, Lemke G, Kurowska-Stolarska M, Maffia P. TAM receptors in cardiovascular disease. Cardiovasc Res. 2019;115:1286–1295. doi: 10.1093/cvr/cvz100CrossrefPubMedGoogle Scholar29.Penberthy KK, Ravichandran KS. Apoptotic cell recognition receptors and scavenger receptors. Immunol Rev. 2016;269:44–59. doi: 10.1111/imr.12376CrossrefPubMedGoogle Scholar30.Hanayama R, Tanaka M, Miwa K, Shinohara A, Iwamatsu A, Nagata S. Identification of a factor that links apoptotic cells to phagocytes. Nature. 2002;417:182–187. doi: 10.1038/417182aCrossrefPubMedGoogle Scholar31.Nakaya M, Kitano M, Matsuda M, Nagata S. Spatiotemporal activation of Rac1 for engulfment of apoptotic cells. Proc Natl Acad Sci USA. 2008;105:9198–9203. doi: 10.1073/pnas.0803677105CrossrefPubMedGoogle Scholar32.Kim SY, Kim S, Bae DJ, Park SY, Lee GY, Park GM, Kim IS. Coordinated balance of Rac1 and RhoA plays key roles in determining phagocytic appetite. PLoS One. 2017;12:e0174603. doi: 10.1371/journal.pone.0174603CrossrefPubMedGoogle Scholar33.Vieira OV, Bucci C, Harrison RE, Trimble WS, Lanzetti L, Gruenberg J, Schreiber AD, Stahl PD, Grinstein S. Modulation of Rab5 and Rab7 recruitment to phagosomes by phosphatidylinositol 3-kinase. Mol Cell Biol. 2003;23:2501–2514. doi: 10.1128/MCB.23.7.2501-2514.2003CrossrefPubMedGoogle Scholar34.Vanlandingham PA, Ceresa BP. Rab7 regulates late endocytic trafficking downstream of multivesicular body biogenesis and cargo sequestration. J Biol Chem. 2009;284:12110–12124. doi: 10.1074/jbc.M809277200CrossrefGoogle Scholar35.Stroope C, Nettersheim FS, Coon B, Finney AC, Schwartz MA, Ley K, Rom O, Yurdagul A. Dysregulated cellular metabolism in atherosclerosis: mediators and therapeutic opportunities. Nat Metab. 2024;6:617–638. doi: 10.1038/s42255-024-01015-wCrossrefPubMedGoogle Scholar36.Lai SC, Devenish RJ. LC3-associated phagocytosis (LAP): connections with host autophagy. Cells. 2012;1:396–408. doi: 10.3390/cells1030396CrossrefPubMedGoogle Scholar37.Doran AC. Inflammation resolution: implications for atherosclerosis. Circ Res. 2022;130:130–148. doi: 10.1161/CIRCRESAHA.121.319822CrossrefPubMedGoogle Scholar38.Wang Y, Subramanian M, Yurdagul A, Barbosa-Lorenzi VC, Cai B, de Juan-Sanz J, Ryan TA, Nomura M, Maxfield FR, Tabas I. Mitochondrial fission promotes the continued clearance of apoptotic cells by macrophages. Cell. 2017;171:331.e22–345.e22. doi: 10.1016/j.cell.2017.08.041CrossrefGoogle Scholar39.Kidani Y, Bensinger SJ. Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity. Immunol Rev. 2012;249:72–83. doi: 10.1111/j.1600-065X.2012.01153.xCrossrefPubMedGoogle Scholar40.Viaud M, Ivanov S, Vujic N, Duta-Mare M, Aira LE, Barouillet T, Garcia E, Orange F, Dugail I, Hainault I, et al. Lysosomal cholesterol hydrolysis couples efferocytosis to anti-inflammatory oxysterol production. Circ Res. 2018;122:1369–1384. doi: 10.1161/CIRCRESAHA.117.312333CrossrefPubMedGoogle Scholar41.Yvan-Charvet L, Pagler TA, Seimon TA, Thorp E, Welch CL, Witztum JL, Tabas I, Tall AR. ABCA1 and ABCG1 protect against oxidative stress–induced macrophage apoptosis during efferocytosis. Circ Res. 2010;106:1861–1869. doi: 10.1161/CIRCRESAHA.110.217281CrossrefPubMedGoogle Scholar42.Fond AM, Lee CS, Schulman IG, Kiss RS, Ravichandran KS. Apoptotic cells trigger a membrane-initiated pathway to increase ABCA1. J Clin Invest. 2015;125:2748–2758. doi: 10.1172/JCI80300CrossrefPubMedGoogle Scholar43.Yalcinkaya M, Tall AR. Cholesterol crystals as triggers of NLRP3 inflammasome activation in atherosclerosis. Curr Atheroscler Rep. 2025;27:1–9. doi: 10.1007/s11883-025-01323-wCrossrefGoogle Scholar44.Grebe A, Hoss F, Latz E. NLRP3 Inflammasome and the IL-1 pathway in atherosclerosis. Circ Res. 2018;122:1722–1740. doi: 10.1161/CIRCRESAHA.118.311362CrossrefPubMedGoogle Scholar45.Cui D, Thorp E, Li Y, Wang N, Yvan-Charvet L, Tall AR, Tabas I. Pivotal advance: macrophages become resistant to cholesterol-induced death after phagocytosis of apoptotic cells. J Leukoc Biol. 2007;82:1040–1050. doi: 10.1189/jlb.0307192CrossrefPubMedGoogle Scholar46.Patterson MT, Firulyova MM, Xu Y, Hillman H, Bishop C, Zhu A, Hickok GH, Schrank PR, Ronayne CE, Caillot Z, et al. Trem2 promotes foamy macrophage lipid uptake and survival in atherosclerosis. Nat Cardiovasc Res. 2023;2:1015–1031. doi: 10.1038/s44161-023-00354-3CrossrefPubMedGoogle Scholar47.Zernecke A, Erhard F, Weinberger T, Schulz C, Ley K, Saliba AE, Cochain C. Integrated single-cell analysis-based classification of vascular mononuclear phagocytes in mouse and human atherosclerosis. Cardiovasc Res. 2023;119:1676–1689. doi: 10.1093/cvr/cvac161CrossrefPubMedGoogle Scholar48.Piollet M, Porsch F, Rizzo G, Kapser F, Schulz DJ, Kiss MG, Schlepckow K, Morenas-Rodriguez E, Sen MO, Gropper J. TREM2 protects from atherosclerosis by limiting necrotic core formation. Nat Cardiovasc Res. 2024;3:269–282. doi: 10.1038/s44161-024-00429-9CrossrefPubMedGoogle Scholar49.Zhang S, Weinberg S, DeBerge M, Gainullina A, Schipma M, Kinchen JM, Ben-Sahra I, Gius DR, Yvan-Charvet L, Chandel NS, et al. Efferocytosis fuels requirements of fatty acid oxidation and the electron transport chain to polarize macrophages for tissue repair. Cell Metab. 2019;29:443.e5–456.e5. doi: 10.1016/j.cmet.2018.12.004CrossrefGoogle Scholar50.Merlin J, Ivanov S, Dumont A, Sergushichev A, Gall J, Stunault M, Ayrault M, Vaillant N, Castiglione A, Swain A, et al. Non-canonical glutamine transamination sustains efferocytosis by coupling redox buffering to oxidative phosphorylation. Nat Metab. 2021;3:1313–1326. doi: 10.1038/s42255-021-00471-yCrossrefPubMedGoogle Scholar51.Yurdagul A, Subramanian M, Wang X, Crown SB, Ilkayeva OR, Darville L, Kolluru GK, Rymond CC, Gerlach BD, Zheng Z, et al. Macrophage metabolism of apoptotic cell-derived arginine promotes continual efferocytosis and resolution of injury. Cell Metab. 2020;31:518.e10–533.e10. doi: 10.1016/j.cmet.2020.01.001CrossrefGoogle Scholar52.Sukka SR, Ampomah PB, Darville LN, Ngai D, Wang X, Kuriakose G, Xiao Y, Shi J, Koomen JM, McCusker RH, et al. Efferocytosis drives a tryptophan metabolism pathway in macrophages to promote tissue resolution. Nat Metab. 2024;6:1736–1755. doi: 10.1038/s42255-024-01115-7CrossrefPubMedGoogle Scholar53.Ampomah PB, Cai B, Sukka SR, Gerlach BD, Yurdagul A, Wang X, Kuriakose G, Darville LN, Sun Y, Sidoli S, et al. Macrophages use apoptotic cell-derived methionine and DNMT3A during efferocytosis to promote tissue resolution. Nat Metab. 2022;4:444–457. doi: 10.1038/s42255-022-00551-7CrossrefPubMedGoogle Scholar54.Gerlach BD, Ampomah PB, Yurdagul A, Liu C, Lauring MC, Wang X, Kasikara C, Kong N, Shi J, Tao W, et al. Efferocytosis induces macrophage proliferation to help resolve tissue injury. Cell Metab. 2021;33:2445.e8–2463.e8. doi: 10.1016/j.cmet.2021.10.015CrossrefGoogle Scholar55.Soto-Heredero G, Gómez de Las Heras MM, Gabandé-Rodríguez E, Oller J, Mittelbrunn M. Glycolysis–a key player in the inflammatory response. FEBS J. 2020;287:3350–3369. doi: 10.1111/febs.15327CrossrefPubMedGoogle Scholar56.Schilperoort M, Ngai D, Katerelos M, Power DA, Tabas I. PFKFB2-mediated glycolysis promotes lactate-driven continual efferocytosis by macrophages. Nat Metab. 2023;5:431–444. doi: 10.1038/s42255-023-00736-8CrossrefPubMedGoogle Scholar57.Morioka S, Perry JS, Raymond MH, Medina CB, Zhu Y, Zhao L, Serbulea V, Onengut-Gumuscu S, Leitinger N, Kucenas S, et al. Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release. Nature. 2018;563:714–718. doi: 10.1038/s41586-018-0735-5CrossrefPubMedGoogle Scholar58.Ngai D, Schilperoort M, Tabas I. Efferocytosis-induced lactate enables the proliferation of pro-resolving macrophages to mediate tissue repair. Nat Metab. 2023;5:2206–2219. doi: 10.1038/s42255-023-00921-9CrossrefPubMedGoogle Scholar59.Wang YT, Trzeciak AJ, Rojas WS, Saavedra P, Chen YT, Chirayil R, Etchegaray JI, Lucas CD, Puleston DJ, Keshari KR, et al. Metabolic adaptation supports enhanced macrophage efferocytosis in limited-oxygen environments. Cell Metab. 2023;35:316.e6–331.e6. doi: 10.1016/j.cmet.2022.12.005CrossrefGoogle Scholar60.Thorp E, Vaisar T, Subramanian M, Mautner L, Blobel C, Tabas I. Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein Kinase Cδ, and p38 mitogen-activated protein kinase (MAPK). J Biol Chem. 2011;286:33335–33344. doi: 10.1074/jbc.M111.263020CrossrefPubMedGoogle Scholar61.Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM, Graham DK. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood. 2007;109:1026–1033. doi: 10.1182/blood-2006-05-021634CrossrefPubMedGoogle Scholar62.Driscoll WS, Vaisar T, Tang J, Wilson CL, Raines EW. Macrophage ADAM17 deficiency augments CD36-dependent apoptotic cell uptake and the linked anti-inflammatory phenotype. Circ Res. 2013;113:52–61. doi: 10.1161/CIRCRESAHA.112.300683CrossrefPubMedGoogle Scholar63.Handberg A, Levin K, Højlund K, Beck-Nielsen H. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation. 2006;114:1169–1176. doi: 10.1161/CIRCULATIONAHA.106.626135CrossrefPubMedGoogle Scholar64.Handberg A, Skjelland M, Michelsen AE, Sagen EL, Krohg-Sørensen K, Russell D, Dahl A, Ueland T, Øie E, Aukrust P, et al. Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability. Stroke. 2008;39:3092–3095. doi: 10.1161/STROKEAHA.108.517128CrossrefPubMedGoogle Scholar65.García-Monzón C, Lo Iacono O, Crespo J, Romero-Gómez M, García-Samaniego J, Fernández-Bermejo M, Domínguez-Díez A, Rodríguez De Cía J, Sáez A, Porrero JL, et al. Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease. Eur J Clin Invest. 2014;44:65–73. doi: 10.1111/eci.12192CrossrefPubMedGoogle Scholar66.Liu G, Wang J, Park YJ, Tsuruta Y, Lorne EF, Zhao X, Abraham E. High mobility group protein-1 inhibits phagocytosis of apoptotic neutrophils through binding to phosphatidylserine. J Immunol. 2008;181:4240–4246. doi: 10.4049/jimmunol.181.6.4240CrossrefGoogle Scholar67.Wang Y, Zhang W, Xu Y, Wu D, Gao Z, Zhou J, Qian H, He B, Wang G. Extracellular HMGB1 impairs macrophage-mediated efferocytosis by suppressing the Rab43-controlled cell surface transport of CD91. Front Immunol. 2022;13:767630. doi: 10.3389/fimmu.2022.767630CrossrefPubMedGoogle Scholar68.Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity. 2008;29:21–32. doi: 10.1016/j.immuni.2008.05.013CrossrefPubMedGoogle Scholar69.Gilchrist SE, Goudarzi S, Hafizi S. Gas6 inhibits toll-like receptor-mediated inflammatory pathways in mouse microglia via axl and mer. Front Cell Neurosci. 2020;14:576650. doi: 10.3389/fncel.2020.576650CrossrefPubMedGoogle Scholar70.Seneviratne AN, Edsfeldt A, Cole JE, Kassiteridi C, Swart M, Park I, Green P, Khoyratty T, Saliba D, Goddard ME, et al. Interferon regulatory factor 5 controls necrotic core formation in atherosclerotic lesions by impairing efferocytosis. Circulation. 2017;136:1140–1154. doi: 10.1161/CIRCULATIONAHA.117.027844CrossrefPubMedGoogle Scholar71.Lv JJ, Wang H, Zhang C, Zhang TJ, Wei HL, Liu ZK, Ma YH, Yang Z, He Q, Wang LJ, et al. CD147 sparks atherosclerosis by driving M1 phenotype and impairing efferocytosis. Circ Res. 2024;134:165–185. doi: 10.1161/CIRCRESAHA.123.323223CrossrefPubMedGoogle Scholar72.Ait-Oufella H, Kinugawa K, Zoll J, Simon T, Boddaert J, Heeneman S, Blanc-Brude O, Barateau V, Potteaux S, Merval R, et al. Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation. 2007;115:2168–2177. doi: 10.1161/CIRCULATIONAHA.106.662080CrossrefPubMedGoogle Scholar73.Kojima Y, Downing K, Kundu R, Miller C, Dewey F, Lancero H, Raaz U, Perisic L, Hedin U, Schadt E, et al. Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis. J Clin Invest. 2014;124:1083–1097. doi: 10.1172/JCI70391CrossrefPubMedGoogle Scholar74.Overton CD, Yancey PG, Major AS, Linton MF, Fazio S. Deletion of macrophage LDL receptor–related protein increases atherogenesis in the mouse. Circ Res. 2007;100:670–677. doi: 10.1161/01.RES.0000260204.40510.aaCrossrefPubMedGoogle Scholar75.Yancey PG, Blakemore J, Ding L, Fan D, Overton CD, Zhang Y, Linton MF, Fazio S. Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation. Arterioscler Thromb Vasc Biol. 2010;30:787–795. doi: 10.1161/ATVBAHA.109.202051CrossrefPubMedGoogle Scholar76.Nanda V, Downing KP, Ye J, Xiao S, Kojima Y, Spin JM, DiRenzo D, Nead KT, Connolly AJ, Dandona S, et al. CDKN2B regulates TGFβ signaling and smooth muscle cell investment of hypoxic neovessels. Circ Res. 2016;118:230–240. doi: 10.1161/CIRCRESAHA.115.307906CrossrefPubMedGoogle Scholar77.Kasikara C, Schilperoort M, Gerlach B, Xue C, Wang X, Zheng Z, Kuriakose G, Dorweiler B, Zhang H, Fredman G, et al. Deficiency of macrophage PHACTR1 impairs efferocytosis and promotes atherosclerotic plaque necrosis. J Clin Invest. 2021;131:e145275. doi: 10.1172/JCI145275CrossrefPubMedGoogle Scholar78.Silva-Sanchez A, Meza-Perez S, Liu M, Stone SL, Flores-Romo L, Ubil E, Lund FE, Rosenberg AF, Randall TD. Activation of regulatory dendritic cells by Mertk coincides with a temporal wave of apoptosis in neonatal lungs. Sci Immunol. 2023;8:eadc9081. doi: 10.1126/sciimmunol.adc9081CrossrefPubMedGoogle Scholar79.Kojima Y, Werner N, Ye J, Nanda V, Tsao N, Wang Y, Flores AM, Miller CL, Weissman I, Deng H, et al. Proefferocytic therapy promotes transforming growth factor-β signaling and prevents aneurysm formation. Circulation. 2018;137:750–753. doi: 10.1161/CIRCULATIONAHA.117.030389CrossrefPubMedGoogle Scholar80.Singla B, Lin HP, Ahn W, Xu J, Ma Q, Sghayyer M, Dong K, Cherian-Shaw M, Zhou J, Huo Y, et al. Loss of myeloid cell-specific SIRPα, but not CD47, attenuates inflammation and suppresses atherosclerosis. Cardiovasc Res. 2022;118:3097–3111. doi: 10.1093/cvr/cvab369CrossrefPubMedGoogle Scholar81.Jarr KU, Ye J, Kojima Y, Ye Z, Gao H, Schmid S, Luo L, Baylis RA, Lotfi M, Lopez N, et al. The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis. Nat Cardiovasc Res. 2022;1:253–262. doi: 10.1038/s44161-022-00023-xCrossrefPubMedGoogle Scholar82.Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010;30:1282–1292. doi: 10.1161/ATVBAHA.108.179739CrossrefPubMedGoogle Scholar83.Heidt T, Courties G, Dutta P, Sager HB, Sebas M, Iwamoto Y, Sun Y, Da Silva N, Panizzi P, Van Der Laan AM, et al. Differential contribution of monocytes to heart macrophages in steady-state and after myocardial infarction. Circ Res. 2014;115:284–295. doi: 10.1161/CIRCRESAHA.115.303567CrossrefPubMedGoogle Scholar84.Bajpai G, Bredemeyer A, Li W, Zaitsev K, Koenig AL, Lokshina I, Mohan J, Ivey B, Hsiao HM, Weinheimer C, et al. Tissue resident CCR2− and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. Circ Res. 2019;124:263–278. doi: 10.1161/CIRCRESAHA.118.314028CrossrefPubMedGoogle Scholar85.Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51:600–606. doi: 10.1016/j.yjmcc.2010.10.033CrossrefPubMedGoogle Scholar86.Francis Stuart SD, De Jesus NM, Lindsey ML, Ripplinger CM. The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction. J Mol Cell Cardiol. 2016;91:114–122. doi: 10.1016/j.yjmcc.2015.12.024CrossrefPubMedGoogle Scholar87.Glinton KE, Ma W, Lantz C, Grigoryeva LS, DeBerge M, Liu X, Febbraio M, Kahn M, Oliver G, Thorp EB. Macrophage-produced VEGFC is induced by efferocytosis to ameliorate cardiac injury and inflammation. J Clin Invest. 2022;132:e140685. doi: 10.1172/JCI140685CrossrefPubMedGoogle Scholar88.DeBerge M, Yeap XY, Dehn S, Zhang S, Grigoryeva L, Misener S, Procissi D, Zhou X, Lee DC, Muller WA, et al. MerTK cleavage on resident cardiac macrophages compromises repair after myocardial ischemia reperfusion injury. Circ Res. 2017;121:930–940. doi: 10.1161/CIRCRESAHA.117.311327CrossrefPubMedGoogle Scholar89.Zhang S, Yeap XY, Grigoryeva L, Dehn S, DeBerge M, Tye M, Rostlund E, Schrijvers D, Zhang ZJ, Sumagin R, et al. Cardiomyocytes induce macrophage receptor shedding to suppress phagocytosis. J Mol Cell Cardiol. 2015;87:171–179. doi: 10.1016/j.yjmcc.2015.08.009CrossrefPubMedGoogle Scholar90.Zhang S, Yeap XY, DeBerge M, Naresh NK, Wang K, Jiang Z, Wilcox JE, White SM, Morrow JP, Burridge PW, et al. Acute CD47 blockade during ischemic myocardial reperfusion enhances phagocytosis-associated cardiac repair. JACC Basic Transl Sci. 2017;2:386–397. doi: 10.1016/j.jacbts.2017.03.013CrossrefPubMedGoogle Scholar91.Maier JA, Andrés V, Castiglioni S, Giudici A, Lau ES, Nemcsik J, Seta F, Zaninotto P, Catalano M, Hamburg NM. Aging and vascular disease: a multidisciplinary overview. J Clin Med. 2023;12:5512. doi: 10.3390/jcm12175512CrossrefPubMedGoogle Scholar92.Rymut N, Heinz J, Sadhu S, Hosseini Z, Riley CO, Marinello M, Maloney J, MacNamara KC, Spite M, Fredman G. Resolvin D1 promotes efferocytosis in aging by limiting senescent cell-induced MerTK cleavage. FASEB J. 2020;34:597–609. doi: 10.1096/fj.201902126RCrossrefPubMedGoogle Scholar93.Han Y, Kim SY. Endothelial senescence in vascular diseases: current understanding and future opportunities in senotherapeutics. Exp Mol Med. 2023;55:1–12. doi: 10.1038/s12276-022-00906-wCrossrefPubMedGoogle Scholar94.Incalza MA, D’Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018;100:1–19. doi: 10.1016/j.vph.2017.05.005CrossrefPubMedGoogle Scholar95.Yamashita A, Noma T, Nakazawa A, Saito S, Fujioka K, Zempo N, Esato K. Enhanced expression of matrix metalloproteinase-9 in abdominal aortic aneurysms. World J Surg. 2001;25:259–265. doi: 10.1007/s002680020062CrossrefPubMedGoogle Scholar96.Apovian CM, Bigornia S, Mott M, Meyers MR, Ulloor J, Gagua M, McDonnell M, Hess D, Joseph L, Gokce N. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol. 2008;28:1654–1659. doi: 10.1161/ATVBAHA.108.170316CrossrefPubMedGoogle Scholar97.Mao QY, He SY, Hu QY, Lu Y, Niu YX, Li XY, Zhang HM, Qin L, Su Q. Advanced glycation end products (AGEs) inhibit macrophage efferocytosis of apoptotic β cells through binding to the receptor for AGEs. J Immunol. 2022;208:1204–1213. doi: 10.4049/jimmunol.2100695CrossrefGoogle Scholar98.Liebold I, Meyer S, Heine M, Kuhl A, Witt J, Eissing L, Fischer A, Koop A, Kluwe J, Schulze Zur Wiesch J, et al. TREM2 regulates the removal of apoptotic cells and inflammatory processes during the progression of NAFLD. Cells. 2023;12:341. doi: 10.3390/cells12030341CrossrefPubMedGoogle Scholar99.Shi H, Wang X, Sloas C, Gerlach B, Yurdagul A, Moore MP, Jung EJ, Mirshahi F, Ronzoni L, Sanyal AJ, et al. Impaired TIM4-mediated efferocytosis by liver macrophages contributes to fibrosis in metabolic dysfunction-associated steatohepatitis. Sci Transl Med. 2025;17:eadv2106. doi: 10.1126/scitranslmed.adv2106CrossrefPubMedGoogle Scholar100.Shi H, Moore MP, Wang X, Tabas I. Efferocytosis in liver disease. JHEP Rep. 2024;6:100960. doi: 10.1016/j.jhepr.2023.100960CrossrefPubMedGoogle Scholar101.Xu Y, Hillman H, Chang M, Barrow F, Ivanov S, Revelo XS, Williams JW. Identification of conserved and tissue-restricted transcriptional profiles for lipid associated macrophages. Commun Biol. 2025;8:953. doi: 10.1038/s42003-025-08387-zCrossrefPubMedGoogle Scholar102.Han CZ, Juncadella IJ, Kinchen JM, Buckley MW, Klibanov AL, Dryden K, Onengut-Gumuscu S, Erdbrügger U, Turner SD, Shim YM, et al. Macrophages redirect phagocytosis by non-professional phagocytes and influence inflammation. Nature. 2016;539:570–574. doi: 10.1038/nature20141CrossrefPubMedGoogle Scholar103.Bennett MR, Gibson DF, Schwartz SM, Tait JF. Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine. Circ Res. 1995;77:1136–1142. doi: 10.1161/01.res.77.6.1136CrossrefPubMedGoogle Scholar104.Clarke MCH, Talib S, Figg NL, Bennett MR. Vascular smooth muscle cell apoptosis induces interleukin-1–directed inflammation: effects of hyperlipidemia-mediated inhibition of phagocytosis. Circ Res. 2010;106:363–372. doi: 10.1161/CIRCRESAHA.109.208389CrossrefPubMedGoogle Scholar105.Nakaya M, Watari K, Tajima M, Nakaya T, Matsuda S, Ohara H, Nishihara H, Yamaguchi H, Hashimoto A, Nishida M, et al. Cardiac myofibroblast engulfment of dead cells facilitates recovery after myocardial infarction. J Clin Invest. 2017;127:383–401. doi: 10.1172/JCI83822CrossrefPubMedGoogle Scholar106.Romana-Souza B, Chen L, Leonardo TR, Chen Z, DiPietro LA. Dermal fibroblast phagocytosis of apoptotic cells: a novel pathway for wound resolution. FASEB J. 2021;35:e21443. doi: 10.1096/fj.202002078rCrossrefPubMedGoogle Scholar107.Yoon H, Choi SI, Kim EK. Uptake of cell debris and enhanced expression of inflammatory factors in response to dead cells in corneal fibroblast cells. Exp Eye Res. 2020;194:108017. doi: 10.1016/j.exer.2020.108017CrossrefPubMedGoogle Scholar108.Dini L, Pagliara P, Carlà EC. Phagocytosis of apoptotic cells by liver: a morphological study. Microsc Res Tech. 2002;57:530–540. doi: 10.1002/jemt.10107CrossrefPubMedGoogle Scholar109.Hess KL, Tudor KS, Johnson JD, Osati-Ashtiani F, Askew DS, Cook-Mills JM. Human and murine high endothelial venule cells phagocytose apoptotic leukocytes. Exp Cell Res. 1997;236:404–411. doi: 10.1006/excr.1997.3745CrossrefPubMedGoogle Scholar110.Kirsch T, Woywodt A, Beese M, Wyss K, Park JK, Erdbruegger U, Hertel B, Haller H, Haubitz M. Engulfment of apoptotic cells by microvascular endothelial cells induces proinflammatory responses. Blood. 2007;109:2854–2862. doi: 10.1182/blood-2006-06-026187CrossrefPubMedGoogle Scholar111.Chen Q, Stone PR, McCowan LME, Chamley LW. Phagocytosis of necrotic but not apoptotic trophoblasts induces endothelial cell activation. Hypertension. 2006;47:116–121. doi: 10.1161/01.HYP.0000196731.56062.7cCrossrefPubMedGoogle Scholar112.Wu J, Liu S, Banerjee O, Shi H, Xue B, Ding Z. Disturbed flow impairs MerTK-mediated efferocytosis in aortic endothelial cells during atherosclerosis. Theranostics. 2024;14:2427–2441. doi: 10.7150/thno.93036CrossrefPubMedGoogle Scholar113.Liu S, Wu J, Banerjee O, Xue B, Shi H, Ding Z. Big data analytics and scRNA-seq in human aortic aneurysms and dissections: role of endothelial MerTK. Theranostics. 2025;15:202–215. doi: 10.7150/thno.103851CrossrefPubMedGoogle Scholar114.Iyoda T, Shimoyama S, Liu K, Omatsu Y, Akiyama Y, Maeda Y, Takahara K, Steinman RM, Inaba K. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med. 2002;195:1289–1302. doi: 10.1084/jem.20020161CrossrefGoogle Scholar115.Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392:86–89. doi: 10.1038/32183CrossrefPubMedGoogle Scholar116.Morelli AE, Larregina AT, Shufesky WJ, Zahorchak AF, Logar AJ, Papworth GD, Wang Z, Watkins SC, Falo LD, Thomson AW. Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood. 2003;101:611–620. doi: 10.1182/blood-2002-06-1769CrossrefPubMedGoogle Scholar117.Krispin A, Bledi Y, Atallah M, Trahtemberg U, Verbovetski I, Nahari E, Zelig O, Linial M, Mevorach D. Apoptotic cell thrombospondin-1 and heparin-binding domain lead to dendritic-cell phagocytic and tolerizing states. Blood. 2006;108:3580–3589. doi: 10.1182/blood-2006-03-013334CrossrefPubMedGoogle Scholar118.Kool M, van Loo G, Waelput W, De Prijck S, Muskens F, Sze M, van Praet J, Branco-Madeira F, Janssens S, Reizis B, et al. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity. 2011;35:82–96. doi: 10.1016/j.immuni.2011.05.013CrossrefPubMedGoogle Scholar119.Chen Z, Moyana T, Saxena A, Warrington R, Jia Z, Xiang J. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer. 2001;93:539–548. doi: 10.1002/ijc.1365CrossrefPubMedGoogle Scholar120.Torchinsky MB, Garaude J, Martin AP, Blander JM. Innate immune recognition of infected apoptotic cells directs TH17 cell differentiation. Nature. 2009;458:78–82. doi: 10.1038/nature07781CrossrefPubMedGoogle Scholar121.Wigren M, Rattik S, Yao Mattisson I, Tomas L, Grönberg C, Söderberg I, Alm R, Sundius L, Ljungcrantz I, Björkbacka H, et al. Lack of ability to present antigens on major histocompatibility complex class II molecules aggravates atherosclerosis in ApoE−/− mice. Circulation. 2019;139:2554–2566. doi: 10.1161/CIRCULATIONAHA.118.039288CrossrefPubMedGoogle Scholar122.Ngai D, Sukka SR, Tabas I. Crosstalk between efferocytic myeloid cells and T-cells and its relevance to atherosclerosis. Front Immunol. 2024;15:1403150. doi: 10.3389/fimmu.2024.1403150CrossrefPubMedGoogle Scholar123.Sharma M, Schlegel MP, Afonso MS, Brown EJ, Rahman K, Weinstock A, Sansbury BE, Corr EM, van Solingen C, Koelwyn GJ, et al. Regulatory T cells license macrophage pro-resolving functions during atherosclerosis regression. Circ Res. 2020;127:335–353. doi: 10.1161/CIRCRESAHA.119.316461CrossrefPubMedGoogle Scholar124.Proto JD, Doran AC, Gusarova G, Yurdagul A, Sozen E, Subramanian M, Islam MN, Rymond CC, Du J, Hook J, et al. Regulatory T cells promote macrophage efferocytosis during inflammation resolution. Immunity. 2018;49:666.e6–677.e6. doi: 10.1016/j.immuni.2018.07.015CrossrefGoogle Scholar125.Morimoto K, Janssen WJ, Fessler MB, McPhillips KA, Borges VM, Bowler RP, Xiao YQ, Kench JA, Henson PM, Vandivier RW. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol. 2006;176:7657–7665. doi: 10.4049/jimmunol.176.12.7657CrossrefGoogle Scholar126.Zhang Y, Wang Y, Zhou D, Zhang LS, Deng FX, Shu S, Wang LJ, Wu Y, Guo N, Zhou J, et al. Angiotensin II deteriorates advanced atherosclerosis by promoting MerTK cleavage and impairing efferocytosis through the AT1R/ROS/p38 MAPK/ADAM17 pathway. Am J Physiol Cell Physiol. 2019;317:C776–C787. doi: 10.1152/ajpcell.00145.2019CrossrefPubMedGoogle Scholar127.Cai B, Thorp EB, Doran AC, Sansbury BE, Daemen MJ, Dorweiler B, Spite M, Fredman G, Tabas I. MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis. J Clin Invest. 2017;127:564–568. doi: 10.1172/JCI90520CrossrefPubMedGoogle Scholar128.Seeley EH, Liu Z, Yuan S, Stroope C, Cockerham E, Rashdan NA, Delgadillo LF, Finney AC, Kumar D, Das S, et al. Spatially resolved metabolites in stable and unstable human atherosclerotic plaques identified by mass spectrometry imaging. Arterioscler Thromb Vasc Biol. 2023;43:1626–1635. doi: 10.1161/ATVBAHA.122.318684CrossrefPubMedGoogle Scholar129.Gastanadui MG, Margaroli C, Litovsky S, Richter RP, Wang D, Xing D, Wells JM, Gaggar A, Nanda V, Patel RP, et al. Spatial transcriptomic approach to understanding coronary atherosclerotic plaque stability. Arterioscler Thromb Vasc Biol. 2024;44:e264–e276. doi: 10.1161/ATVBAHA.123.320330CrossrefPubMedGoogle Scholar130.Sun J, Singh P, Shami A, Kluza E, Pan M, Djordjevic D, Michaelsen NB, Kennback C, van der Wel NN, Orho-Melander M, et al. Spatial transcriptional mapping reveals site-specific pathways underlying human atherosclerotic plaque rupture. J Am Coll Cardiol. 2023;81:2213–2227. doi: 10.1016/j.jacc.2023.04.008CrossrefPubMedGoogle Scholar
Advertisement
RecommendedAugust 2017MerTK Cleavage on Resident Cardiac Macrophages Compromises Repair After Myocardial Ischemia Reperfusion Injury
Matthew DeBerge,
Xin Yi Yeap,
Shirley Dehn,
Shuang Zhang,
Lubov Grigoryeva,
Sol Misener,
Daniel Procissi,
Xin Zhou,
Daniel C. Lee,
William A. Muller,
Xunrong Luo,
Carla Rothlin,
Ira Tabas, and
[...]Edward B. Thorp
+10 authors
July 2013Enhanced Efferocytosis of Apoptotic Cardiomyocytes Through Myeloid-Epithelial-Reproductive Tyrosine Kinase Links Acute Inflammation Resolution to Cardiac Repair After Infarction
Elaine Wan,
Xin Yi Yeap,
Shirley Dehn,
Rachael Terry,
Margaret Novak,
Shuang Zhang,
Shinichi Iwata,
Xiaoqiang Han,
Shunichi Homma,
Konstantinos Drosatos,
Jon Lomasney,
David M. Engman,
Stephen D. Miller,
Douglas E. Vaughan,
John P. Morrow,
Raj Kishore, and
[...]Edward B. Thorp
+13 authors
January 2024Macrophage Heterogeneity and Efferocytosis: Beyond the M1/M2 Dichotomy
Prabhash Kumar Jha,
Masanori Aikawa, and
[...]Elena Aikawa
+0 authors
Advertisement
Submit a Response to This ArticleCloseCompose eLetterTitle:Comment text:Contributors(all fields are required)Remove ContributorFirst Name:Last Name:Email:Affiliation:Add Another Contributor
Statement of Competing InterestsCompeting Interests?YESNOPlease describe the competing interests
CancelSubmitView full text|Download PDF
Comment Response
Arteriosclerosis, Thrombosis, and Vascular Biology
Submit
Browse
Browse
Collections
Subject Terms
AHA Journal Podcasts
Trend Watch
Resources
Resources
CME
Journal Metrics
Early Career Resources
AHA Journals @ Meetings
Information
Information
For Authors
For Reviewers
For Subscribers
For International Users
Arteriosclerosis, Thrombosis, and Vascular Biology
Circulation
Circulation Research
Hypertension
Stroke
Journal of the American Heart Association
Circulation: Arrhythmia and Electrophysiology
Circulation: Cardiovascular Imaging
Circulation: Cardiovascular Interventions
Circulation: Population Health and Outcomes
Circulation: Genomic and Precision Medicine
Circulation: Heart Failure
Stroke: Vascular and Interventional Neurology
Annals of Internal Medicine: Clinical Cases
This page is managed by Wolters Kluwer Health, Inc. and/or its affiliates or subsidiaries. Wolters Kluwer Privacy Policy
Your California Privacy Choices
Manage Cookie Preferences
Back to top
National Center
7272 Greenville Ave.Dallas, TX 75231Customer Service
1-800-AHA-USA-1
1-800-242-8721Hours
Monday - Friday: 7 a.m. – 7 p.m. CT
Saturday: 9 a.m. - 5 p.m. CT
Closed on SundaysTax Identification Number
13-5613797
ABOUT
US
About the
AHA/ASA
Annual
report
AHA Financial
Information
Careers
International
Programs
Latest Heart and
Stroke News
AHA/ASA Media
Newsroom
GET
INVOLVED
Donate
Advocate
Volunteer
ShopHeart
ShopCPR
OUR
SITES
American Heart
Association
American Stroke
Association
CPR &
ECC
Go Red For
Women
More
Sites
AHA Careers
AHA Privacy Policy
Medical Advice Disclaimer
Copyright Policy
Accessibility Statement
Ethics Policy
Conflict of Interes Policy
Linking Policy
Whistleblower Policy
Content Editorial Guidelines
Diversity
Suppliers & Providers
State Fundraising Notices
©2026 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.The
American Heart Association is a qualified 501(c)(3) tax-exempt organization.*Red Dress ™ DHHS, Go Red ™
AHA ; National Wear Red Day® is a registered trademark.
Copy link✓Thanks for sharing!Find any serviceAddToAnyMore…Privacy Preference CenterWhen you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device. Because we respect your right to privacy, you can choose not to allow certain types of cookies on our website. Click on the different category headings to find out more and manage your cookie preferences. However, blocking some types of cookies may impact your experience on the site and the services we are able to offer.
Privacy & Cookie NoticeManage Consent PreferencesStrictly Necessary CookiesAlways ActiveThese cookies are necessary for the website to function. They are usually set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, this may have an effect on the proper functioning of (parts of) the site.View Vendor Details‎Functional Cookies
Functional Cookies These cookies enable the website to provide enhanced functionality, user experience and personalization, and may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies, then some or all of these services may not function properly.View Vendor Details‎Performance Cookies
Performance Cookies These cookies support analytic services that measure and improve the performance of our site. They
help us know which pages are the most and least popular and see how visitors move around the site.View Vendor Details‎Advertising Cookies
Advertising Cookies These cookies may collect insights to issue personalized content and advertising on our own and other websites, and may be set through our site by third party providers.
If you do not allow these cookies, you may still see basic advertising on your browser that is generic and not based on your interests.View Vendor Details‎Back ButtonVendors List Search IconFilter IconClear checkbox label labelApply CancelConsent Leg.Interest checkbox label label checkbox label label checkbox label labelAllow AllReject All Confirm My Choices
Now Reading:More Than a Cleanup Crew: The Expanding Biology of EfferocytosisTrack CitationsAdd to favoritesShareGet AccessPREVIOUS ARTICLERegulation of Insulin Transcytosis Across Endothelium in Metabolic Health and DiseasePreviousNEXT ARTICLEImmune Cell Regulation of Zebrafish Heart RegenerationNext__("articleCrossmark.closePopup")
